Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional)

The Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders funding opportunity is issued by the National Institutes of Health through the National Institute of Neurological Disorders and Stroke. This program is designed to address a critical gap in the development of biomarkers by supporting rigorous analytical validation of methods used to measure biomarkers intended for use in clinical trials or clinical practice. Biomarkers are essential tools in understanding disease progression, improving clinical trial design, and enabling better therapeutic decision-making, yet many promising biomarkers fail to advance beyond early discovery due to insufficient validation. This opportunity specifically targets that gap by supporting validation efforts that ensure biomarkers are reliable, reproducible, and suitable for defined clinical contexts of use. The program supports research activities that optimize and evaluate the performance characteristics of biomarker detection methods. These activities include assessing accuracy, precision, analytical sensitivity and specificity, and establishing reference ranges and quality control procedures. Applicants are expected to clearly define one or two contexts of use for the biomarker and provide evidence of prior preliminary testing demonstrating sufficient promise. The funding also emphasizes standardization across sites and encourages multi-site collaboration to ensure reproducibility across different laboratories and operators. While multi-site studies are expected, single-site applications may be accepted with appropriate scientific justification. Funding is provided through a cooperative agreement mechanism, meaning that NIH program staff will have substantial involvement throughout the project period. Budgets are not capped but must reflect the actual needs of the proposed work, and project periods may extend up to four years. There is no cost-sharing requirement for this opportunity. Funds may be used for research activities directly related to analytical validation, including study design, sample collection, statistical analysis, and development of quality assurance procedures. Applicants must also include detailed milestone plans, team management strategies, and data sharing plans in alignment with NIH policies. Eligibility for this funding opportunity is broad and includes higher education institutions, nonprofit organizations, for-profit entities, and government agencies at various levels, including tribal governments and independent school districts. However, foreign organizations and non-U.S. components of U.S. organizations are not eligible to apply, although foreign components may be included under certain conditions. Individuals with the necessary expertise must work through eligible organizations to submit applications. Applicants must complete required registrations such as SAM, Grants.gov, and eRA Commons prior to submission. The application process requires submission through NIH-approved systems such as ASSIST or Grants.gov Workspace. Applicants must follow strict formatting and submission guidelines outlined in the NIH Application Guide and the funding announcement. Required components include a research strategy detailing the analytical validation approach, a statistical analysis plan, milestone timelines, team management plans, and, where applicable, clinical trial documentation and intellectual property considerations. Applications are evaluated based on significance, innovation, rigor, feasibility, and the expertise of the research team. Key dates for this opportunity include multiple recurring submission deadlines, with cycles occurring in February and June annually through June 2026. Applications are due by 5:00 PM local time of the applicant organization. Review cycles follow each submission, with scientific review, advisory council review, and earliest start dates outlined in the schedule. The opportunity expires in June 2026 but follows a recurring structure, suggesting continued issuance or similar future opportunities. Applicants are encouraged to engage NIH program staff early in the planning process to ensure alignment with program priorities and expectations.

Strong emphasis on rigor, reproducibility, and clearly defined context of use; ensure robust preliminary data and detailed analytical validation plan; include measurable milestones and justify feasibility across sites